Header Logo

Connection

RAJKUMAR VENKATRAMANI to Adolescent

Back to Details
This is a "connection" page, showing publications RAJKUMAR VENKATRAMANI has written about Adolescent.
RAJKUMAR VENKATRAMANI
Connection Strength
2.074
Adolescent
  1. Extremity rhabdomyosarcoma in children, adolescents and young adults: A report from Children's Oncology Group trials. Cancer. 2025 Jun 15; 131(12):e35929.
    View in: PubMed
    Score: 0.065
  2. Nonorbital, Nonparameningeal Head and Neck Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Jun; 72(6):e31673.
    View in: PubMed
    Score: 0.064
  3. Multicenter Retrospective Analysis of Pediatric Differentiated Thyroid Carcinoma: Treatment Practices and Outcomes Prior to Pediatric American Thyroid Association Guidelines Implementation. Pediatr Blood Cancer. 2025 Apr; 72(4):e31545.
    View in: PubMed
    Score: 0.063
  4. Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial. Pediatr Blood Cancer. 2025 Feb; 72(2):e31436.
    View in: PubMed
    Score: 0.062
  5. Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2024 Oct; 71(10):e31200.
    View in: PubMed
    Score: 0.061
  6. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
    View in: PubMed
    Score: 0.061
  7. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2023 Dec; 70(12):e30701.
    View in: PubMed
    Score: 0.058
  8. Soft Tissue and Visceral Organ Sarcomas With BCOR Alterations. J Pediatr Hematol Oncol. 2022 07 01; 44(5):195-200.
    View in: PubMed
    Score: 0.052
  9. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer. 2022 04; 69(4):e29511.
    View in: PubMed
    Score: 0.051
  10. Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study. J Clin Oncol. 2021 12 10; 39(35):3927-3937.
    View in: PubMed
    Score: 0.050
  11. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer. 2021 08; 45(4):100768.
    View in: PubMed
    Score: 0.049
  12. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis. J Pediatr Hematol Oncol. 2021 03 01; 43(2):e215-e218.
    View in: PubMed
    Score: 0.048
  13. Neurocutaneous Melanocytosis and Leptomeningeal Melanoma. J Pediatr Hematol Oncol. 2021 03 01; 43(2):e195-e197.
    View in: PubMed
    Score: 0.048
  14. BCOR-CCNB3 fusion-positive clear cell sarcoma of the kidney. Pediatr Blood Cancer. 2020 04; 67(4):e28151.
    View in: PubMed
    Score: 0.044
  15. Malignant melanoma incidence among children and adolescents in Texas and SEER 13, 1995-2013. Pediatr Blood Cancer. 2019 06; 66(6):e27648.
    View in: PubMed
    Score: 0.042
  16. Pediatric Bronchial Carcinoid Tumors: A Case Series and Review of the Literature. J Pediatr Hematol Oncol. 2019 01; 41(1):67-70.
    View in: PubMed
    Score: 0.041
  17. A Multicenter Retrospective Review of Pediatric Leydig Cell Tumor of the Testis. J Pediatr Hematol Oncol. 2019 01; 41(1):74-76.
    View in: PubMed
    Score: 0.041
  18. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma. Thyroid. 2018 11; 28(11):1450-1454.
    View in: PubMed
    Score: 0.041
  19. Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. Pediatr Blood Cancer. 2019 01; 66(1):e27469.
    View in: PubMed
    Score: 0.041
  20. Alveolar soft part sarcoma in children and young adults: A report of 69 cases. Pediatr Blood Cancer. 2018 05; 65(5):e26953.
    View in: PubMed
    Score: 0.039
  21. Borderline Ovarian Tumor in the Pediatric and Adolescent Population: A Case Series and Literature Review. J Pediatr Adolesc Gynecol. 2018 Feb; 31(1):48-54.
    View in: PubMed
    Score: 0.038
  22. Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials. Pediatr Blood Cancer. 2017 Jul; 64(7).
    View in: PubMed
    Score: 0.036
  23. Juvenile Granulosa Cell Tumor of the Ovary: A Clinicopathologic Study. J Pediatr Adolesc Gynecol. 2017 Feb; 30(1):138-143.
    View in: PubMed
    Score: 0.035
  24. Gemcitabine-induced radiation recall myositis in a patient with relapsed nasopharyngeal carcinoma. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):e19-e22.
    View in: PubMed
    Score: 0.035
  25. Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):465-70.
    View in: PubMed
    Score: 0.033
  26. Risk-Based Therapy for Localized Osteosarcoma. Pediatr Blood Cancer. 2016 Mar; 63(3):412-7.
    View in: PubMed
    Score: 0.033
  27. Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis. Am J Clin Oncol. 2014 Dec; 37(6):592-6.
    View in: PubMed
    Score: 0.031
  28. Successful treatment of recurrent metastatic nasopharyngeal carcinoma with oxaliplatin and doxorubicin. J Pediatr Hematol Oncol. 2014 Jul; 36(5):e307-9.
    View in: PubMed
    Score: 0.030
  29. Pulmonary function abnormalities in childhood cancer survivors treated with bleomycin. Pediatr Blood Cancer. 2014 Sep; 61(9):1679-84.
    View in: PubMed
    Score: 0.030
  30. Correlation of pulmonary function abnormalities with dose volume histograms in children treated with lung irradiation. Pediatr Pulmonol. 2015 Jun; 50(6):596-603.
    View in: PubMed
    Score: 0.030
  31. Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. Pediatr Blood Cancer. 2014 Jul; 61(7):1277-81.
    View in: PubMed
    Score: 0.029
  32. Nuclear protein in testis midline carcinoma misdiagnosed as adamantinoma. J Clin Oncol. 2014 May 20; 32(15):e57-60.
    View in: PubMed
    Score: 0.029
  33. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer. 2014 Apr; 61(4):756-9.
    View in: PubMed
    Score: 0.029
  34. Inflammatory myofibroblastic tumors in childhood. Pediatr Hematol Oncol. 2013 Oct; 30(7):640-5.
    View in: PubMed
    Score: 0.029
  35. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. PLoS One. 2013; 8(7):e68416.
    View in: PubMed
    Score: 0.028
  36. Correlation of clinical and dosimetric factors with adverse pulmonary outcomes in children after lung irradiation. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):942-8.
    View in: PubMed
    Score: 0.028
  37. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. Pediatr Blood Cancer. 2013 Jul; 60(7):1103-7.
    View in: PubMed
    Score: 0.027
  38. An exploratory epidemiological study of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1324-6.
    View in: PubMed
    Score: 0.026
  39. Radiological features of Gorham's disease. Clin Radiol. 2012 Aug; 67(8):782-8.
    View in: PubMed
    Score: 0.026
  40. Supratentorial ependymoma in children: to observe or to treat following gross total resection? Pediatr Blood Cancer. 2012 Mar; 58(3):380-3.
    View in: PubMed
    Score: 0.024
  41. Gorham's disease and diffuse lymphangiomatosis in children and adolescents. Pediatr Blood Cancer. 2011 Apr; 56(4):667-70.
    View in: PubMed
    Score: 0.024
  42. Single site metastatic rhabdomyosarcoma: An INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) pooled analysis. Eur J Cancer. 2025 Oct 16; 229:115793.
    View in: PubMed
    Score: 0.016
  43. The International Soft Tissue Sarcoma Consortium: The baseline analysis of rhabdomyosarcoma data. Cancer. 2025 Jul 15; 131(14):e35974.
    View in: PubMed
    Score: 0.016
  44. The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group. HGG Adv. 2025 Jul 10; 6(3):100466.
    View in: PubMed
    Score: 0.016
  45. Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2025 Sep 01; 123(1):54-62.
    View in: PubMed
    Score: 0.016
  46. Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. JCO Precis Oncol. 2025 Feb; 9:e2400556.
    View in: PubMed
    Score: 0.016
  47. Late Events Occurring After 5?Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Jan; 72(1):e31421.
    View in: PubMed
    Score: 0.016
  48. Outcomes of relapsed favorable-histology Wilms tumor in non-clinical trial setting. Pediatr Blood Cancer. 2025 01; 72(1):e31347.
    View in: PubMed
    Score: 0.015
  49. Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2024 Dec 20; 42(36):4263-4270.
    View in: PubMed
    Score: 0.015
  50. Outcomes for patients with perineal and perianal rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 2024 Nov; 71(11):e31303.
    View in: PubMed
    Score: 0.015
  51. The impact of margins and re-resection in pediatric synovial sarcoma. Cancer Med. 2024 Sep; 13(17):e70207.
    View in: PubMed
    Score: 0.015
  52. Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2024 Jul; 71(7):e31009.
    View in: PubMed
    Score: 0.015
  53. Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children's Oncology Group. Cancer. 2024 Jul 15; 130(14):2493-2502.
    View in: PubMed
    Score: 0.015
  54. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2024 Apr; 71(4):e30847.
    View in: PubMed
    Score: 0.015
  55. Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30556.
    View in: PubMed
    Score: 0.014
  56. Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001-2017. Cancer Med. 2023 02; 12(3):3644-3656.
    View in: PubMed
    Score: 0.013
  57. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022 09; 172:367-386.
    View in: PubMed
    Score: 0.013
  58. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)?. ESMO Open. 2021 10; 6(5):100250.
    View in: PubMed
    Score: 0.013
  59. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021 09; 22(9):1312-1321.
    View in: PubMed
    Score: 0.012
  60. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer. 2021 03 15; 127(6):946-956.
    View in: PubMed
    Score: 0.012
  61. Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2021 01 15; 127(2):275-283.
    View in: PubMed
    Score: 0.012
  62. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma. Pediatr Blood Cancer. 2021 01; 68(1):e28741.
    View in: PubMed
    Score: 0.012
  63. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
    View in: PubMed
    Score: 0.012
  64. Endoscopic Ultrasound in an Adolescent With Rectal Adenocarcinoma and Lynch Syndrome. J Pediatr Gastroenterol Nutr. 2020 06; 70(6):e136.
    View in: PubMed
    Score: 0.011
  65. Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. J Pediatr Gastroenterol Nutr. 2019 05; 68(5):695-699.
    View in: PubMed
    Score: 0.011
  66. Cholangiocarcinoma Among Children and Adolescents: A Review of the Literature and Surveillance, Epidemiology, and End Results Program Database Analysis. J Pediatr Gastroenterol Nutr. 2018 01; 66(1):e12-e18.
    View in: PubMed
    Score: 0.010
  67. Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a single institution. Histopathology. 2017 Nov; 71(5):813-822.
    View in: PubMed
    Score: 0.009
  68. Myofibroma in Infancy and Childhood. J Pediatr Hematol Oncol. 2017 04; 39(3):e136-e139.
    View in: PubMed
    Score: 0.009
  69. Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol. 2017 03; 39(2):97-102.
    View in: PubMed
    Score: 0.009
  70. Pilot Feasibility Study of Comprehensive Pulmonary Evaluation Following Lung Radiation Therapy. J Pediatr Hematol Oncol. 2015 Oct; 37(7):e412-8.
    View in: PubMed
    Score: 0.008
  71. Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma. J Pediatr Hematol Oncol. 2015 Aug; 37(6):e399-401.
    View in: PubMed
    Score: 0.008
  72. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31.
    View in: PubMed
    Score: 0.008
  73. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clin Cancer Res. 2014 Dec 15; 20(24):6314-23.
    View in: PubMed
    Score: 0.008
  74. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov. 2014 Aug; 4(8):928-41.
    View in: PubMed
    Score: 0.008
  75. Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines. Cancer Epidemiol Biomarkers Prev. 2014 Jun; 23(6):1109-14.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.